BiomX Inc. filed a Form D with the Securities and Exchange Commission on 2026-01-20.
BiomX Inc. filed a Form D notice of an exempt securities offering with the SEC on January 20, 2026. The filing reports $3.30M sold. Its industry group is Pharmaceuticals. It names Jonathan Solomon (Chief Executive Officer), Marina Wolfson (Chief Financial Officer), Merav Bassan (Chief Development Officer) (SEC Form D, January 20, 2026).
Sell to companies like BiomX Inc? Enter your website and see 10 with a filed reason to buy from you this month. Free.
Opens in a new tab. No signup.
New Form D on file · 2026-01-20 · the record
Pitching, partnering or investing alongside them? See who really runs and owns BiomX Inc.
Free to see. No signup.
More on the people and the money behind BiomX Inc., from the filings we hold.
Pharmaceuticals raises filed within 90 days of this one, largest first.
Get an email when BiomX Inc. files again: a new raise, a leadership change, a layoff or an IPO filing. One email first to confirm; nothing else until you click it. At most one a day, one click to stop. Free for up to 3 companies.
We'll show it in your MentionFox inbox when BiomX Inc. raises, hires or launches. No email unless you switch it on.
Watch BiomX Inc. →Get the full cited report on BiomX Inc.
What the filing shows about BiomX Inc.
Only in the Full Report: Who Runs It, And How To Reach Them · Warning Bells · Who Pays Them, And Who They Are Up Against.
Example from a real report (our sample on Target): “Target eliminated approximately 1,800 corporate positions, with around 1,000 employees receiving layoff notices and the remainder accounted for by eliminating open roles.” Source: NBC News
A Full Report on BiomX Inc.: verified, sourced, every claim cited, ready in a few minutes. See pricing.
Saved here on this device in the meantime, so nothing is lost either way.
Full funding history for BiomX Inc. →
This is the company's own disclosure. A payment disclosed on a Form D is a disclosed use of proceeds, not a finding of wrongdoing.
Each marker is one filing. The larger marker is the filing this page is about.
Trailing twelve months. 157 filings in Pharmaceuticals, totalled by week. The dot is this raise, $3.30M, on the same scale — one filing against the whole group's total, so it sits low by construction.
On the filing as: Executive Officer, Director.
Jonathan Solomon is named as Chief Executive Officer on the Form D that BiomX Inc. filed with the SEC on 20 January 2026, one of 10 people that filing names.
On the filing as: Executive Officer.
Marina Wolfson is named as Chief Financial Officer on the Form D that BiomX Inc. filed with the SEC on 20 January 2026, one of 10 people that filing names.
On the filing as: Executive Officer.
Merav Bassan is named as Chief Development Officer on the Form D that BiomX Inc. filed with the SEC on 20 January 2026, one of 10 people that filing names.
Susan Blum is named as Director on the Form D that BiomX Inc. filed with the SEC on 20 January 2026, one of 10 people that filing names.
Jesse Goodman is named as Director on the Form D that BiomX Inc. filed with the SEC on 20 January 2026, one of 10 people that filing names.
Russell Greig is named as Director on the Form D that BiomX Inc. filed with the SEC on 20 January 2026, one of 10 people that filing names.
Jonathan Leff is named as Director on the Form D that BiomX Inc. filed with the SEC on 20 January 2026, one of 10 people that filing names.
Gregory Merril is named as Director on the Form D that BiomX Inc. filed with the SEC on 20 January 2026, one of 10 people that filing names.
Alan Moses is named as Director on the Form D that BiomX Inc. filed with the SEC on 20 January 2026, one of 10 people that filing names.
Eddie Williams is named as Director on the Form D that BiomX Inc. filed with the SEC on 20 January 2026, one of 10 people that filing names.
10 people named on the filing — 3 holding an executive role and 7 as directors only.
Named as of the 2026-01-20 filing. Titles and locations are exactly as the filing states — not independently confirmed elsewhere.
No investor is drawn from a Form D — the form states how many invested and never who.
What the filing shows about BiomX Inc.
Only in the Full Report: Who Runs It, And How To Reach Them · Warning Bells · Who Pays Them, And Who They Are Up Against.
Example from a real report (our sample on Target): “Target eliminated approximately 1,800 corporate positions, with around 1,000 employees receiving layoff notices and the remainder accounted for by eliminating open roles.” Source: NBC News
A Full Report on BiomX Inc.: verified, sourced, every claim cited, ready in a few minutes. See pricing.
What the Full Report on BiomX Inc. covers
Plus the sections for what you are deciding, which you pick after ordering.
A real finished report, first screen. Opens in a new tab.
Not ready to order yet? Keep this snapshot.
Sends this preview to you once; we won't add you to any list
You land back on this company when you are in.
Not ready to upgrade? Keep this one in view instead.
Watchlist BiomX Inc.You get an alert in MentionFox the next time this company shows up.
If you're behind BiomX Inc.: the weeks after a raise are watched the same way — by other investors sizing you up, and by founders checking who just got funded. FoxPlug turns your commits, deploys, and releases into that story automatically. GetFoxChat puts a guide on your own site so the people this filing just sent you don't leave after one page.
Sourced from the filing index on sec.gov.
Each opens in a new tab, filled in for BiomX Inc.. With no account yet, you sign up free and land on the result.
https://mentionfox.com/funding/biomx-inc-form-d-26000001